Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy

As patients with non-small cell lung cancer (NSCLC) and wild-type epidermal growth factor receptor (EGFR) are resistant to treatment with erlotinib or gefitinib, potential chemosensitizers are required to potentiate wild-type EGFR NSCLC cells to erlotinib/gefitinib treatment. The present study repor...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Med Rep
Auteurs principaux: Li, Yang-Ling, Hu, Xiu, Li, Qing-Yu, Wang, Fei, Zhang, Bo, Ding, Ke, Tan, Bi-Qin, Lin, Neng-Ming, Zhang, Chong
Format: Artigo
Langue:Inglês
Publié: D.A. Spandidos 2018
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6131653/
https://ncbi.nlm.nih.gov/pubmed/30106133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2018.9347
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires